Shots:

• The FDA’s approval follows multiple studies with various age group evaluating baqsimi (glucagon- 3mg) nasal powder vs glucagon injection formulation in patients with diabetes aged 4yrs and older
• Collective study results demonstrated noninferiority data to glucagon injection formulation in raising blood glucose level after insulin-induced hypoglycemia- 100% patients reach treatment success  i.e- increase in plasma glucose levels to ≥ 70 mg/dL or a ≥20 mg/dL rise in plasma glucose from nadir within 30 minutes post receiving glucagon
• Baqsimi is a dry nasal spray form of glucagon- ready to use with no reconstitution or priming required in a single- fixed 3 mg dose- to be absorbed in the nose and is expected to be available within one month in the US

Click here to­ read full press release/ article

Ref: Eli Lilly | Image: Eli Lilly